^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Anruixi (zuberitamab)
i
Other names: HS006, HS 006, RHCACD20MA, HS-006, RHCACD 20MA, RHCAD-20-MA
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Zhejiang Hisun
Drug class:
CD20 inhibitor
Related drugs:
26d
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trial. (PubMed, J Immunother Cancer)
Zuberitamab (375 mg/m2) plus CHOP was non-inferior to R-CHOP regarding ORR but exhibited a higher CR rate and was well tolerated in CD20-positive, previously untreated Chinese patients with DLBCL.
Clinical • P3 data • Journal
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Anruixi (zuberitamab)
1m
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy (clinicaltrials.gov)
P2, N=135, Not yet recruiting, BioRay Pharmaceutical Co., Ltd.
New P2 trial
|
cyclosporine • Anruixi (zuberitamab)
Share via
